The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial

Peter Sandercock, Joanna M. Wardlaw, Richard I. Lindley, Martin Dennis, Geoff Cohen, Gordon Murray, Karen Innes, Graham Venables, Anna Czlonkowska, Adam Kobayashi, Stefano Ricci, Veronica Murray, Eivind Berge, Karsten Bruins Slot, Graeme J. Hankey, Manuel Correia, Andre Peeters, Karl Matz, Phillippe Lyrer, Gord GubitzStephen J. Phillips, Antonio Arauz, Colin Baigent, David Chadwick, Pippa Tyrrell, Gordon Lowe, Rory Collins, Philip Bath, Jan Van Gijn, Richard Gray, Robert Hart, Salim Yusuf, Alison Clark, David Perry, Vera Soosay, David Buchanan, Sheila Grant, Eleni Sakka, Jonathan Drever, Pauli Walker, Indee Herath, Ann Leigh Brown, Paul Chmielnik, Christopher Armit, Andrea Walton, Mischa Hautvast, Steff Lewis, Graeme Heron, Sylvia Odusanya, Pam Linksted, Ingrid Kane, Will Whiteley, Robin Sellar, Philip White, Peter Keston, Andrew Farrell, Zoe Morris, Hector Miranda, Lisa Blackwell

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

1056 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial'. En conjunto forman una huella única.

Medicine & Life Sciences